Therapeutic Asset Ratings
172 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Lactobacillus Rhamnosus Gg
Multiple Sclerosis
Medstar Health Research Institute
Early P1
C
(34)
Liraglutide
Multiple Sclerosis
University of Chicago
Early P1
C
(34)
nk042
Multiple Sclerosis
The Affiliated Hospital of Xuzhou Medical University
Early P1
C
(34)
qt-019c
Multiple Sclerosis
Tianjin Huanhu Hospital
Early P1
C
(34)
SDM-8
Multiple Sclerosis
Brigham and Women's Hospital
Early P1
C
(34)
Ucar T-Cell
Multiple Sclerosis
Tianjin Huanhu Hospital
Early P1
C
(34)
Universal Bcma Car-T
Multiple Sclerosis
Xuanwu Hospital, Beijing
Early P1
C
(34)
Universal Cd19 Car-T
Multiple Sclerosis
Xuanwu Hospital, Beijing
Early P1
C
(34)
[18F] FZTA
Multiple Sclerosis
Washington University School of Medicine
D
(28)
Anti-T-lymphocyte globulin
Multiple Sclerosis
Ciceri Fabio
D
(28)
Calculus Bovis Sativus
Multiple Sclerosis
Tongji Hospital
N/A
D
(28)
CT-100 DiNaMo
Multiple Sclerosis
Click Therapeutics, Inc.
N/A
D
(28)
EMAPUNIL
Multiple Sclerosis
Imperial College London
N/A
D
(28)
Etifoxine
Multiple Sclerosis
Imperial College London
N/A
D
(28)
Fuzuloparib
Multiple Sclerosis
Centre National de Rééducation Fonctionnelle et de Réadaptation
N/A
D
(28)
GLUCAGON-LIKE PEPTIDE 1, HUMAN
Multiple Sclerosis
Northwestern University
D
(28)
Mtm-H-001
Multiple Sclerosis
Beijing GoBroad Hospital
N/A
D
(28)
Tamsulosin
Multiple Sclerosis
Centre Hospitalier Universitaire de Nīmes
N/A
D
(28)
Tysabri
Multiple Sclerosis
Biogen
D
(28)
Zeposia
Multiple Sclerosis
Corium Innovations, Inc.
D
(28)
Zeprumetostat
Multiple Sclerosis
Centre National de Rééducation Fonctionnelle et de Réadaptation
N/A
D
(28)
pb018
Multiple Sclerosis
Polpharma Biologics International AG
P1
NR
(0)
Showing 151 to 172 of 172 assets
Previous
Page 7 of 7
Next